004720.KS
PharmGen Science, Inc.
KSC · Healthcare · Drug Manufacturers - General · KR
KRW 3,140.00
−0.63%Year over year
Reported trailing growth
- Revenue
- +0.4%
- EBITDA
- -3.4%
- EBIT
- -62.1%
- EPS
- —
- Free cash flow
- +496.4%
- Operating cash flow
- +1074.7%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +4.7%
- EBITDA
- -0.8%
- EBIT
- -13.7%
- Net income
- —
- EPS
- —
- Free cash flow
- +34.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026